Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL3818 in Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer
NCT02558348Phase 2Terminated
- Sponsor
- Advenchen Laboratories
- Start
- Nov 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib in endometrial cancer (EC), ovarian cancer and Cervical Cancer (CC), sponsored by Advenchen Laboratories. Primary endpoints: Number of Participants with Adverse Events as a Measure of Safety and Tolerability, Maximum Tolerated Dose and 1 more. Started Nov 2015; status: terminated.
02
Drugs
anlotinib
03
Conditions
endometrial cancer (EC)ovarian cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT02558348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02558348.